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Summary One hundred and nineteen patients with breast cancer had 2 or more lesions removed for
oestrogen (REJ) or progesterone receptor (RPr) assay, either synchronously (on 38 occasions) or after an
interval (on 91 occasions). In all but 7 both receptors were assayed for each lesion. The assays did not agree
on the presence or absence of RE, alone, RP, alone or the combination of both receptors in 11, 13 and 16%
respectively of the synchronous samples, compared with 23, 30 and 43% of the asynchronous samples. The
differences between the synchronous and asynchronous samples were significant for the combined receptors
(P=0.007) but not for RE, (P=0.176) or RPc alone (P=0.077). Variation between asynchronous biopsies
was greater when the earlier lesion contained RP, (18/37 disagreed) than when it did not (8/50) disagreed,
P=0.0023). This was not true for oestrogen receptor. In those remaining receptor positive there was only a
weak correlation between the first and second values (Spearman rank correlation coefficient, p = 0.39 for REV,
P<0.02, and 0.45 for RPC, 0.05 <P<0.1). Receptor levels and receptor status may change with time. Biopsy
is most appropriate at the time when systemic treatment is proposed.
Oestrogen and progesterone receptor analyses are
used- widely in the selection of patients with
advanced breast cancer for endocrine treatment. It
has been established that 50-60% of patients whose
tumours contain cytosol oestrogen receptors (RE,)
at the time of treatment will respond to endocrine
manoeuvres, and that only - 10% of patients will
respond when REr is absent (Barnes et al., 1979;
McGuire, 1980; King, 1980). The proportion of
patients likely to respond is higher when
progesterone receptor (RPC) is also present (Barnes
et al., 1979; McGuire, 1980; King, 1980, Degenshein
et al., 1980).
Many metastases are not readily accessible for
biopsy and treatment is often decided on the basis
of receptor studies assessed in the primary tumours
or lymph nodes before dissemination is apparent.
The extent to which receptor status may vary with
time is unknown, but may be of considerable
importance when the choice of systemic treatments
is being considered.
In this report we describe our experience of
receptor analyses in patients who have had more
than one lesion submitted for assay.
Materials and methods
Specimens of human breast cancer were obtained
from primary or secondary lesions at the
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Withington and Christie Hospitals in Manchester.
A portion of the tumour was trimmed of excess fat
and connective tissue and frozen immediately in
liquid nitrogen. Specimens were stored in liquid
nitrogen until the assay was performed.
Thirty-eight patients had more than one lesion
excised at the same time for receptor assay. Ninety-
one second and third biopsies were taken after an
interval ranging from 3 weeks to 58 months, from
83 patients. Both REc -and RPC were known for
each lesion on 84 occasions. In 4 patients RE, but
not RP, was known, and in 3 RP, only was known
for both lesions.
In 8 of the asynchronous biopsies an advanced
primary lesion was biopsed twice. In 62 the initial
lesion was the primary tumour and the subsequent
lesion a soft tissue or lymph node metastasis. In the
remainder all assays were carried out on soft tissue
or nodal metastases.
One patient who had 2 discrete, homolateral
primary tumours was included among the
synchronously-biopsied patients. No other patient
with separate primary tumours was included.
Cytosol oestrogen and progesterone receptors
were measured by a dextran-coated charcoal
method using [3H]-oestradiol and [3H]-R5020 (a
synthetic progestogen with a high affinity for RPr as
the radiologands for RE, and RP, respectively
(Barnes et al., 1979). Specific binding was
suppressed in parallel incubations with an excess of
unlabelled diethylstilboestrol (for RE) or unlabelled
norethisterone acetate (for RP). The concentration
of hormone binding sites was determined by
Scatchard analysis. Protein concentration was
determined by the method of Lowry. The minimum
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value of hormone binding which allowed a patient
to be classified as RE,+ was 5fmolmg-' cytosol
protein. The minimum value for RP, + was
15fmol mg- cytosol protein. In 5 cases a satisfactory
Scatchard plot was obtained for RPC but the level
of binding fell below the confidence limit when
corrected for the cytosol protein concentration. The
minimum concentration of protein which allowed a
negative result to be accepted as technically reliable
was 0.7 mgml- l.
Patients were excluded if they had taken
tamoxifen in the month preceding their biopsy.
Apart from this, 20 patients had some form of
hormone treatment in the interval between biopsies.
Seven had tamoxifen, 6 ovarian ablation,
stilboestrol, 1 norethisterone, and 5 had a
combination of some of these, in sequence. In one
other, the natural menopause occurred between
biopsies.
Eleven of the patients who had asynchronous
biopsies were pre-menopausal, and 66 were post-
menopausal at the time of both biopsies.
Patients with technically unsatisfactory assays e.g.
negative results with low cytosol protein
concentrations were also excluded. Three patients
who had cutaneous lesions removed for receptor
assay but not sent for histological confirmation of
the clinical diagnosis of malignancy have been
included. In all other patients malignancy was
confirmed by histological examination.
Results
Synchronous biopsies
The assays disagreed on the presence or absence of
RE, and RPC and on the combinations of REr and
RP, (Double receptor status) in 11, 13 and 16% of
biopsies respectively (Table I).
Asynchronous biopsies
RE, status varied in 23% of the paired assays.
Although higher, this proportion was not
significantly different from that found in
synchronous biopsies (Table I). The extent of
variation was similar whether the initial lesion
contained receptor or not (Table II). RP, status
differed in 30% of the asynchronous samples.
When the first lesion contained RPc, 49% of
patients did not have RPc in a later biopsy. When
the first lesion did not contain RPC, it was found in
16% of the subsequent samples (Table II). When
both receptors were considered together 43% of
asynchronous biopsies did not maintain the same
classification.
Five patients in whom there was RPC activity in
one biopsy had evidence of RPC activity below the
Table I Variation of receptor status in synchronous and
asynchronous biopsies. (No. with receptor status
changed/total)
Synchronous Asynchronous
(%) (%) RPc
(a) when the conventional limit of sensitivity for RP,
assay (15 fmolmg'- cytosol protein) is used.
REC 4/38 (11) 20/88 (23) 0.176*
RPC 5/38 (13) 26/87 (30) 0.077*
REC & RPC 6/38 (16)
(b) when RPr
accepted.
values between
36/84 (43) 0.007*
0 and 15 fmolmg-' are
Synchronous Asynchronous
(%) (%)
RPC 3/38 (8) 23/87 (27) 0.035*
REC & RPC 4/38 (11) 33/84 (39) 0.003*
x2 test.
accepted limit of sensitivity in another. If these are
accepted as containing RPc there is a small
reduction in the extent of the variation, but the
significant differences between synchronous and
asynchronous samples remain (Table I).
When neither receptor was present initially one
or the other was found in a subsequent biopsy in
28% of patients. When REc alone or both receptors
were present in the first biopsy, 45-50% of patients
did not maintain their receptor classification. Four
of 5 patients in whom RPc was the only receptor
found in the first biopsy differed in a later receptor
analysis. The differences in the extent of variation
between the groups were not significant (Table III).
Exclusion of the patients who had had some
form of hormone treatment in the interval between
biopsies did not reduce the proprtion of cases in
which some variation occurred (Table IV).
Thirteen of the 26 patients (50%) in whom the
interval between the biopsies was <1 year had
Table II Variation in asynchronous samples and initial
receptor status
Receptor status at
second biopsy
+ve -ve
REC status at first biopsy +ve 43 11
-ve 9 25
RPr status at first biopsy +ve 19 18
-ve 8 42VARIATION OF RECEPTORS IN BREAST CANCER
Table III Double receptor status in asynchronous biopsies
Receptor status at second biopsy
ER,+/PRC+ ERC+/PRC ERc-/PRc+ ERc-/PRc-
Receptor status ERc+/PRc+ 16 9 1 5
at first biopsy ER,+/PRc- 5 10 0 4
ERc /PRc+ 0 3 1 1
ERc /PRc- 0 6 2 21
Table IV Effects of endocrine treatment between biopsies.
(No. of patients with status changed/total)
Rieated Not treated
(%) (0)
REC 5/20 (25) 15/68 (22)
RPC 6/20 (30) 20/67 (30)
REC & RPC 8/20 (40) 28/64 (44)
some change in their receptor status compared with
23 of the 58 patients (40%) whose interval was
more than one year (X2 = 1.45, P=0.23).
The initial levels of receptor were similar whether
RE, or RP0 status changed or not (Figure 1). Six
of 23 patients (26%) who had low values of RE,
REc
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(<50fmol mg - cytosol protein) in their first
biopsy became RE, -ve compared with 5 of 33
patients (15%) whose tumours contained
>50fmolmg-' of RE, initially (P=0.25, Exact
Test). Three of 5 patients in whom there was less
than 50ffmolmg-t cytosol protein of RP0 in their
first biopsy and 15/32 patients in whom the first
biopsy contained >50fmolmg-t of RP0 became
RP, -ve (P=0.56). In those patients who remained
RE, or RP0 + there was only a weak correlation
between the initial and subsequent values (Figures 2
& 3; for REc, p=0.39, P<0.02; for RPc p=0.45,
0.05<P<0.01).
The mean concentration of RE, in those patients
who were RE, -ve initially but in whom RE, was
found in later biopsy was 22fmolmg-' (range 6-
59fmolmg-'). When RP, was found only in the
later biopsy the mean concentration was
41 fmolmg-' (range 17-144fmolmg-1).
Discussion
The proportion of patients in whom the ER, status
was consistent is similar to that quoted in other
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Figure 1 Initial REC or RPC values in receptor-
positive first biopsies related to REC or RPC status of
the subsequent biopsy.
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Figure 2 First and second REC values in RE, positive
asynchronous biopsies.
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Figure 3 First and second RPC values in RPC positive
asynchronous biopsies.
reports which give a range of 66-85% agreement
between biopsies (Brennan et al., 1979. Webster et
al., 1978. Rosen et al., 1977. Allegra et al., 1980).
Less data are available on the variation of RP,
between sites and with time, but other workers have
noted a similar inconsistency (Koenders et al., 1980.
Matsumoto et al., 1978). In this study loss of
progesterone receptor was particularly common. In
only one patient could this have been due to the
menopause occurring in the interval between the
biopsies.
Previous reports have not considered the changes
which may take place in the combined receptor
status. Our finding of a change in 43% of
asynchronous biopsies casts serious doubt on the
value of classifying patients at an early stage in
their disease.
Several reports have been published on the
response to endocrine treatment in relation to
receptor status which fail to distinguish between
contemporary or past receptor estimations (Bloom
et al., 1980. MacFarlane et al., 1980. Mosely et al.,
1980). It is essential to distinguish between
contemporary and previous data when reporting
response in relation to receptor status.
Some authors have suggested that a response is
more likely with high concentrations of RE, than
with low ones and that the measurement of PRC
may be unnecessary (Lippman & Allegra, 1980.
Osborne et al., 1980. Paridaens et al., 1980).
Concentrations of RE, showed a similar
inconsistency and it cannot be assumed that initial
high concentrations will be maintained later in the
course of the disease. The concentrations of
receptor that occurred when receptor was found
only in a later biopsy were usually low. The
changes from RE, to RE,. that occurred may not
indicate a higher probability of response. When
RPr is considered, the concentration is less
important than the presence or absence of receptor
and the significance of changes from RPc- to RPc+
cannot be diminished.
We were not able to confirm the findings of
Webster et al. (1978) who found that variation in
receptor status was related to the interval between
biopsies. The variation was neither confined to the
patients who were initially oestrogen receptor
positive as has been suggested (Leake et al. 1981)
nor to those with only low values of REc or RPc.
There are several possible reasons for this
variation. In a small proportion of cases, despite,
histological evidence of malignancy and
satisfactory cytosol protein concentrations the
material analysed may not have been tumour. We
have no information on the cellularity or
inflammatory cell content of these samples. In some
cases anoxia of the tumour during mastectomy may
have caused low concentrations of receptor to
denature and led to false negative status for some
primary tumours. These factors are equally
probable in both synchronous and asynchronous
biopsies and would not explain the differences seen
in the two groups. Variation, particularly of the
RP, probably represents a true discrepancy in status
with time. These changes cannot be predicted by
any earlier receptor assays.
The majority of lesions biopsied in this study
were superficial. The chest wall or the regional
nodes have not been shown to be preferential sites
of recurrence for either RE,+ or REc- primary
tumours. Bone and viscera may be preferred sites
of metastasis for REc, and REc primary tumours
respectively (Campbell et al., 1981). The receptor
status of secondary deposits at these sites may be
easier to predict and information on receptor status
at these sites in relation to previous biopsies would
be of interest.
The clinical significance of this variation in
receptor status with time will only be known when
there are enough patients who have had reliable
estimations both well before and at the time of
endocrine treatment and for whom the response to
treatment is known. Until then it seems prudent,
when possible, to take biopsies for receptor
estimations at the time when systemic treatment is
proposed rather than to rely upon assays performed
at the time ofmastectomy or ofa previous recurrence.
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